Liminatus Pharma (LIMN) Stock Is Trending Overnight — Here’s Why it Spiked Over 30% in After-Hours Sessio

Liminatus Pharma (NASDAQ:LIMN) shares rose 30.49% to $0.15 in after-hours after the company amended and restated its merger agreement with InnocsAI LLC. The revised terms aim to let the deal close before shareholder approval, expected Thursday, with consideration valued at $0.20 per share plus contingent value rights.

Original reporting
Published Jul 2, 2026, 6:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 6:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMergers & acquisitions
Primary signal
$LIMN
Bullish
medium confidence
Mentioned
$LIMN
Relevance
8/10
AlphAI data visualization · based on benzinga.com
Decision brief

The 30-second read

$LIMNBullishMed
01

Why it matters

The amended and restated merger agreement changes the path to closing (expected Thursday) and the consideration mix, which can materially affect deal certainty and dilution expectations for LIMN holders.

02

Market read

Deal-structure revision and a near-term closing timeline are the immediate drivers for LIMN’s after-hours repricing and likely follow-through/volatility into Thursday.

03

What to watch

Execution risk remains (even with faster closing), and the article provides no details on regulatory/financing conditions, while LIMN’s prior 12-month performance (-98.89%) suggests fragile sentiment.

Relevance 8/10Novelty 7/10Timing: after-hours reaction to amended InnocsAI merger terms; closing expected Thursday

Background

Liminatus is an immuno-oncology biotech; the article frames the overnight move as a merger-structure update with InnocsAI LLC.

Company-level read

Ticker impact

$LIMNBullishMedium confidence
Context

Liminatus shares jumped 30.49% after-hours after it amended and restated its merger agreement with InnocsAI, enabling a faster close.

Expected impact

Likely continued elevated volatility and upside bias into the expected Thursday closing, with sharp reversals possible if deal mechanics face delays.

Evidence & confidence

The article discloses a fresh, deal-structure change and a specific timing expectation (close Thursday), which typically drives immediate repricing for microcap M&A targets.

Market effects

Signals ongoing consolidation/financing dynamics in immuno-oncology/cell-therapy, but impact is company-specific given LIMN’s tiny market cap.

Limited broader regional read-through; primarily a US microcap biotech event.

Low global relevance; deal value cited (~$320m) is material for LIMN but not systemically global.

Counterpoint

The stock’s move may be overstated versus deal economics: consideration is capped at 19.99% and includes non-voting preferred plus contingent value rights, which can dilute or be uncertain.

Key entities

  • Liminatus Pharma, Inc.

    NASDAQ-listed immuno-oncology biotech whose shares spiked after-hours on amended InnocsAI merger terms.

  • InnocsAI LLC

    Cell-therapy developer whose equity holders receive a mix of LIMN common stock, capped at 19.99%, plus non-voting convertible preferred and CVRs.

  • Chris Kim

    Liminatus CEO who described the merger as a transformational strategic step.

Related articles

$LIMNMed

Liminatus Partners with Korean Firm for CAR

Liminatus Pharma partners with Synex Consulting to advance its CAR-T cell therapy in South Korea. The Ministry of Food and Drug Safety authorized a Phase 1/2a clinical study. Liminatus went public via a SPAC last year. Shares are down 8.2% to $4.73, with a $6.4M market cap.

$LIMNMed

Liminatus Pharma, Inc. (LIMN): Completion of Acquisition or Disposition of Assets

Liminatus Pharma, Inc. (LIMN) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. EX-2.1 2 tm2619730d1_ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AMENDED AND RESTATED MERGER AGREEMENT dated June 29, 2026 by and among InnocsAI LLC, Delaware limited liability company (the “ Company ”), NamChul Jung, as the Members’ Representative (the “ NamChul Jung ”), and Liminatus Pha

$LIMNMedAI 8/10

Liminatus Pharma Amends Merger Agreement With InnocsAI To Expand Oncology Pipeline

Liminatus Pharma (LIMN) amended its merger agreement with InnocsAI LLC to expand its oncology pipeline. The deal is now expected to close July 2, 2026, before stockholder approval. InnocsAI holders will receive Liminatus common stock and newly designated non-voting convertible preferred issued at $0.20/share, implying ~$320M value, plus CVRs on 20% of future net proceeds.

$AMDMed

AMD aims at NVIDIA with World Labs and Taalas for next-gen AI supremacy

AMD completed acquisitions of World Labs and Taalas, aiming to strengthen its AI capabilities. World Labs, led by Dr. Fei-Fei Li, focuses on spatial AI models, while Taalas specializes in custom silicon for AI. AMD's CEO, Lisa Su, aims to optimize compute platforms and models together. These acquisitions follow NVIDIA's similar moves and could position AMD as a major player in AI infrastructure, with datacenter revenue expected to exceed 80% by 2027.

$PANWMed

Palo Alto Networks Acquires Applied Compute for $4.5 Billion

Palo Alto Networks (PANW) agreed to acquire AI infrastructure startup Applied Compute for $4.5B in an all-stock deal, aiming to integrate AI development with cybersecurity. The transaction, expected to close in Q3 2027, will see Applied Compute's CEO join PANW as Co-Chief AI Officer. Applied Compute reported $100M annualized revenue and a $3.25B private valuation before the acquisition.